Naguib and colleagues developed a combination therapy using CIP2b-loaded PEGylated polymeric nanoparticles (CIP2b-NPs) and PTX to treat type-II endometrial cancer with p53 loss. The gene discussed is TP53; the disease is endometrial cancer.